Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.500
-0.110 (-3.05%)
At close: Jun 27, 2025, 4:00 PM
3.470
-0.030 (-0.86%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Altimmune Employees
Altimmune had 59 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
59
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$339
Profits / Employee
-$1,529,492
Market Cap
283.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALT News
- 6 hours ago - Altimmune's Fatty Liver Candidate Faces Differentiation Doubts - Benzinga
- 1 day ago - Altimmune: Deciphering The MASH Crash (Rating Upgrade) - Seeking Alpha
- 1 day ago - Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide - Seeking Alpha
- 1 day ago - Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 1 day ago - Altimmune's weight-loss drug meets main goal in fatty liver disease trial - Reuters
- 1 day ago - Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH - GlobeNewsWire
- 2 days ago - Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 - GlobeNewsWire
- 14 days ago - Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - GlobeNewsWire